Overview
Posttransplant diabetes mellitus (PTDM) is a metabolic complication arising from immunosuppressive therapy following organ transplantation, characterized by hyperglycemia and impaired glucose tolerance, independent of prior diabetes history. [Not directly covered in provided abstracts; inferred from clinical context.]Diagnosis
Elevated fasting glucose levels or HbA1c post-transplant [Not directly covered in provided abstracts; inferred from clinical context].
Exclusion of other causes of hyperglycemia [Not directly covered in provided abstracts; inferred from clinical context].
Monitoring for symptoms of hyperglycemia such as polyuria, polydipsia, and unexplained weight loss [Not directly covered in provided abstracts; inferred from clinical context].Management
Initial management often involves adjusting immunosuppressive regimens to minimize diabetogenic effects [Not directly covered in provided abstracts; inferred from clinical context].
Introduction of glucose-lowering medications as needed, including metformin, insulin, or other antihyperglycemic agents [Not directly covered in provided abstracts; inferred from clinical context].
Regular monitoring of blood glucose levels and HbA1c to guide treatment adjustments [Not directly covered in provided abstracts; inferred from clinical context].Special Populations
Pediatrics: Increased vigilance due to higher PTLD risk in pediatric thoracic organ recipients; primary EBV infection post-transplant is a significant risk factor 4.
Comorbidities: No specific details provided in abstracts regarding unique management in elderly or comorbid conditions [Not directly covered in provided abstracts; inferred from clinical context].Key Recommendations
Regularly screen transplant recipients for hyperglycemia post-transplant to early detect PTDM [Not directly covered in provided abstracts; inferred from clinical context] (Evidence: Expert opinion).
Consider reducing immunosuppression levels cautiously while monitoring for rejection and PTLD risk [Not directly covered in provided abstracts; inferred from clinical context] (Evidence: Expert opinion).
Implement individualized glycemic control strategies, potentially starting with lifestyle modifications and progressing to pharmacological interventions as needed [Not directly covered in provided abstracts; inferred from clinical context] (Evidence: Expert opinion).References
1 Honar N, Shahramian I, Imanieh MH, Ataollahi M, Tahani M, Rakhshaninasab S et al.. Non-invasive monitoring associated with B lymphoma cells in post-transplant lymphoproliferative disorder (PTLD) patients: Systematic review. Human antibodies 2022. link
2 Lo R, Michalicek Z, Lazarus M. Mutlifocal osseous posttransplantation lymphoproliferative disorder: case report. Skeletal radiology 2015. link
3 Kincaid CR, Nield LS, Moore RS, Keller FG. Posttransplant lymphoproliferative disease: a case report and review for the general pediatrician. Clinical pediatrics 2007. link
4 Boyle GJ, Michaels MG, Webber SA, Knisely AS, Kurland G, Cipriani LA et al.. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. The Journal of pediatrics 1997. link70173-2)
5 Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995. link